Related references
Note: Only part of the references are listed.Delivery materials for siRNA therapeutics
Rosemary Kanasty et al.
NATURE MATERIALS (2013)
Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle
Scott Eliasof et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
Josep Tabernero et al.
CANCER DISCOVERY (2013)
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Nazila Kamaly et al.
CHEMICAL SOCIETY REVIEWS (2012)
Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth
Mohammad Aminur Rahman et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Atelocollagen-mediated Systemic Delivery Prevents Immunostimulatory Adverse Effects of siRNA in Mammals
Shinichiro Inaba et al.
MOLECULAR THERAPY (2012)
Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane
Jonathan E. Zuckerman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Allometric scaling of pegylated liposomal anticancer drugs
Whitney P. Caron et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2011)
Pitfalling in nanomedical targeting of melanoma: a 'clinical' case of misdelivered RNAi Reply
Jonathan E. Zuckerman et al.
PIGMENT CELL & MELANOMA RESEARCH (2011)
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Mark E. Davis et al.
NATURE (2010)
The First Targeted Delivery of siRNA in Humans via a Self-Assembling, Cyclodextrin Polymer-Based Nanoparticle: From Concept to Clinic
Mark E. Davis
MOLECULAR PHARMACEUTICS (2009)
Dose translation from animal to human studies revisited
Shannon Reagan-Shaw et al.
FASEB JOURNAL (2008)
Misinterpreting the Therapeutic Effects of Small Interfering RNA Caused by Immune Stimulation
Marjorie Robbins et al.
HUMAN GENE THERAPY (2008)
Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA
Jeremy D. Heidel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo
Jeremy D. Heidel et al.
CLINICAL CANCER RESEARCH (2007)
Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles
Derek W. Bartlett et al.
BIOCONJUGATE CHEMISTRY (2007)
Ribonucleotide reductase inhibitors and future drug design
J. Shao et al.
CURRENT CANCER DRUG TARGETS (2006)
Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers
MR Dreher et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Lack of interferon response in animals to naked siRNAs
JD Heidel et al.
NATURE BIOTECHNOLOGY (2004)
Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma
RZ Yu et al.
ANALYTICAL BIOCHEMISTRY (2002)
Share Paper
